Update

Connecting Excipients with Drug Patents – New DrugPatentWatch module

New DrugPatentWatch module connects excipients and drug patents In response to user requests, DrugPatentWatch has added a new database of excipients (inactive ingredients) in drugs, and integrated it with our… The post Connecting Excipients with Drug Patents – New DrugPatentWatch module appeared first on DrugPatentWatch – Make Better Decisions.

Vir and GSK Provide Update on ACTIV-3 Trial of VIR-7831 in Hospitalized Adults with COVID-19

Shots: The DSMB has recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature. The recommendation was based on pre-planned safety & efficacy data review of the first 300 patients hospitalized with COVID-19 enrolled in ACTIV-3 The companies will continue discussions with the NIH to further assess the potential …

Vir and GSK Provide Update on ACTIV-3 Trial of VIR-7831 in Hospitalized Adults with COVID-19 Read More »

Say ‘NO’ to Bad Contracts

Are you tired of having to navigate complicated contracts to access the information you need? Let DrugPatentWatch free you from weeks of negotiating complex contracts and let you focus on… The post Say ‘NO’ to Bad Contracts appeared first on DrugPatentWatch – Make Better Decisions.

DrugPatentWatch featured in Inc Magazine

DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited our published interview where Mark Cuban Sounds off on Drug Prices.… The post DrugPatentWatch featured in Inc Magazine appeared first on DrugPatentWatch – Make Better Decisions.

Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

Shots: Regenxbio has reported that the ATMOSPHERE trial evaluating RGX-314 is active and patient screening is ongoing. The study will enroll 300 patients across two RGX-314 dose arms vs ranibizumab, with anticipated initiation of patients dosing in Q1’21 The second trial is expected to be similar in design to ATMOSPHERE with its expected initiation in …

Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD Read More »

Voyager Therapeutics Provides Update on NBIB-1817(VY-AADC) Program to Treat Parkinson Disease

Shots: The P-ll RESTORE-1 study involves assessing NBIb-1817(VY-AADC) for the treatment of Parkinson’s disease. Neuroscience & Voyager will closely work with FDA & DCMB to determine the next clinical trial for RESTORE-1 DSMB request a clinical hold, follows the IND Safety Report submit by Neurocrine Biosciences related to the observation of MRI abnormalities in some …

Voyager Therapeutics Provides Update on NBIB-1817(VY-AADC) Program to Treat Parkinson Disease Read More »

Essential Medicines and Patents

Mark Schultz and Jaci McDole recently used DrugPatentWatch to complete a report on recent trends in the latest editions of the world health organization essential medicines list. Some of their key… The post Essential Medicines and Patents appeared first on DrugPatentWatch – Make Better Decisions.

Jounce Stops Enrollment in P-II EMERGE Study Evaluating Vopratelimab for Lung Cancer

Shots: The company will not expand the P-II EMERGE study that assesses Vopratelimab + ipilimumab in PD-(L)1 inhibitor experienced NSCLC patient. Early evaluation of the study showed that the trial will not meet pre-specified interim criteria for continuation of enrollment The company also reported the first patient dosing in P-II SELECT study assessing Vopratelimab + …

Jounce Stops Enrollment in P-II EMERGE Study Evaluating Vopratelimab for Lung Cancer Read More »

AstraZeneca’s Forxiga (dapagliflozin) Receive NMPA’s Approval for Label Update to Include Data of P-III DECLARE-TIMI 58 Study

Shots: The updated label includes P-III DECLARE-TIMI 58 study that assesses the effect of Forxiga vs PBO on CV outcomes in 17000+ patients with T2D at risk of CV events also assessed key renal 2EPs, across 882 sites in 33 countries The study demonstrated that Forxiga achieved a significant reduction in the composite EP of …

AstraZeneca’s Forxiga (dapagliflozin) Receive NMPA’s Approval for Label Update to Include Data of P-III DECLARE-TIMI 58 Study Read More »

Finding and Evaluating Market Entry Opportunities for a Better ROI

I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities for a Better ROI at the upcoming 13th Portfolio Management & Pipeline Optimization for Generics from September 30th… The post Finding and Evaluating Market Entry Opportunities for a Better ROI appeared first on DrugPatentWatch – Make Better Decisions.

DrugPatentWatch and Bloomberg: Are there too many generic patent challenges?

Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of challengers of each patent is also increasing. Why might this… The post DrugPatentWatch and Bloomberg: Are there too many generic patent challenges? appeared first on DrugPatentWatch – Make Better Decisions.

Lab Manager Ask the Expert

Check out the latest issue of Lab Manager where I discuss my interest in informatics, the complexities of informatics for today’s scientists, and some of the tools available. https://www.labmanager.com/ask-the-expert/trends-in-informatics-22895 The post Lab Manager Ask the Expert appeared first on DrugPatentWatch – Make Better Decisions.

Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition

Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s based on the book Make Better Decisions, which distills insights… The post Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition appeared first on DrugPatentWatch – Make Better Decisions.

The effect of patent expiration on sales of branded competitor drugs in a therapeutic class

DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, and… The post The effect of patent expiration on sales of branded competitor drugs in a therapeutic class appeared first on DrugPatentWatch – Make Better Decisions.

DrugPatentWatch Headlines Swissbiotech Annual Report

The latest Swiss Biotech annual report focuses on the theme of shaping change. Change is a theme DrugPatentWatch is very familiar with — whether it is a matter of tracking… The post DrugPatentWatch Headlines Swissbiotech Annual Report appeared first on DrugPatentWatch – Make Better Decisions.